GATINEAU, QC, February 3rd, 2023. Pharmaflorx Inc. (“Pharmaflorx” or the”Company”), a reputable pharmaceutical company, has received exciting news in the form of a cultivation and sales license from Health Canada. This license represents a significant achievement for the company, marking a key milestone in its operations and highlighting the success of its investment in technology and innovation within its facility.
The issuance of this license by the regulatory agency responsible for overseeing cannabis cultivation in the country, allows Pharmaflorx to grow and sell cannabis nationally, and to apply for export permits, positioning the company for increased success in the global market. Moreover, this license aligns with the GPP and GACP certifications already in place for the facility, which have contributed to its reputation for producing plant-based metabolites of the highest quality.
Pharmaflorx recognizes the importance of complying with international regulations and standards, and the attainment of this license is a testament to the company’s unwavering commitment to meeting and exceeding the highest quality standards. This commitment is further demonstrated by the company’s current pursuit of GMP certification, a milestone it plans to achieve by the end of Q4 2023. Once obtained, Pharmaflorx will be able to ship its products to most international customers, solidifying its position as a leading provider of plant-based metabolites.
The license is also a significant step forward for the company in terms of the advanced technology and innovation being invested in its facility. Pharmaflorx has been working closely with top-tier experts in the field to create one of the most advanced facilities in the world to produce plant-based metabolites for the international market. This license allows the company to continue its investment in technology and innovation, positioning it for long-term success and growth in the industry.
In conclusion, the issuance of this cultivation and sales license is a remarkable accomplishment for Pharmaflorx, solidifying its position as a leading provider of plant-based metabolites in the industry. The company remains committed to meeting and exceeding international quality standards, and this license serves as a validation of its efforts. Pharmaflorx is excited to continue its investment in technology and innovation, positioning itself for even greater success in the future.
